The CMS Innovation Center is approaching the next negotiation cycle for the CGT Access Model. Several considerations will guide the selection of future candidate diseases and potential new model ...

A 49-year-old woman presented with a 6-month history of an itchy lump on her vulva. Examination showed a painless purple mass originating in the labia minora on the left side.

Faced with a young woman whose seizures, of untraceable cause, can’t be stopped by the medical team, a medical student viscerally learns the limits to what can be accomplished by pushing harder.

The nonsteroidal mineralocorticoid receptor antagonist finerenone has been reported to improve kidney and cardiovascular outcomes in persons with type 2 diabetes and chronic kidney disease (CKD).

Supported by grants from the Deutsche Forschungsgemeinschaft, a grant (80735240) from the Deutsche Krebshilfe, the Else Kröner Fresenius Stiftung, the Else Kröner Clinician Scientist Program Munich: ...

New AI-based software for generating patient notes purposely filters out social “chitchat,” but a primary care physician sees serious risks in that practice, for doctors and patients alike.

Private equity firms have gained increasing control of U.S. health care infrastructure. Along with other potential consequences, this growth threatens to undermine progress in health equity.

This Sounding Board announces a new FDA policy that the default requirement for FDA approvals will be one robust pivotal trial plus confirmatory evidence, rather than two trials.

We conducted a trial involving the release of male A. aegypti mosquitoes infected with the wAlbB strain of wolbachia bacteria for the control of dengue in Singapore, a tropical city-state. In this ...

Recent court decisions have treated statements in drug labels as evidence of patent infringement by generic-drug manufacturers. The Supreme Court has an opportunity to address this trend.

Both viral and host factors have contributed to the intensity of influenza activity during the 2025–2026 season. Some of these factors can be managed, whereas others are largely beyond human control.

Recent FDA actions related to leucovorin have caused confusion. There is still a lack of scientific evidence establishing that the drug is a safe and effective treatment for autism.